Loading
LY4064912 / Overweight Or Obesity / Healthy · Phase 1 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registration for LY4064912, a novel investigational drug candidate. The study aims to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers and individuals with overweight or obesity. No efficacy data or results are reported in this registry record.
Phase 1, Interventional, Randomized, Sequential, Double masking, Basic Science purpose. Overweight or Obesity, Healthy; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Part A: LY4064912 (Cohorts 1-6); Part A: LY4064912 (Cohort 6a); Part B: LY4064912 (Cohorts 7-10); Part C: LY4064912 (Cohort 11); Part C: Placebo. Compared with: Part A: Placebo — Placebo Comparator; Part B: Placebo — Placebo Comparator. n = 144. 3 sites: United States, Singapore.
This is a Phase 1 clinical trial registration for LY4064912, a novel investigational drug candidate. The study aims to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers and individuals with overweight or obesity. No efficacy data or results are reported in this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study is in early-phase development. Clinicians should await Phase 2 and later trial results before any clinical application can be considered. Current registry information indicates only safety and tolerability objectives.
Phase 1 safety and tolerability study in healthy volunteers and patients with overweight/obesity; no results reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This study is in early-phase development. Clinicians should await Phase 2 and later trial results before any clinical application can be considered. Current registry information indicates only safety and tolerability objectives.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07152002). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 144 participants (ESTIMATED). Conditions: Overweight or Obesity, Healthy. Interventions: DRUG: LY4064912; DRUG: LY4064912; DRUG: Placebo; DRUG: Placebo. Primary outcome measures: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration , Postdose to Approximately Week 27. Brief summary: The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.